In the latest reverse merger, Vienna's Arsanis serves as vehicle for X4 Pharma's Nasdaq listing
Consider this: a small biotech pins its hopes on its lead program, which for whatever reason later fails. Then comes along a private player looking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
